Catch This Upslisting BEFORE it Happens

Imagine being able to find one of these gems BEFORE the uplisting… [Image] What happens when a stock gets uplisted to the NASDAQ? INVESTORS TAKE NOTICE! Imagine being able to find one of these gems BEFORE the uplisting… You could be in for a real humdinger! Normally, we’re lucky to catch the first trading day of an IPO when it debuts on a major exchange. That’s why today’s newsletter is SO CRITICAL! I found this idea through a promotion buried deep in my inbox with few details. It’s a cancer treatment company currently trading over-the-counter (OTC) with plans to uplist to the NASDAQ…we just don’t have an exact date… …but, I may have an idea to help us narrow it down. Accustem Sciences (OTC: ACUT) 1-month trading range: $0.7101 - $1.9500 Typical average daily volume: ~9,000 Float: ~6.1million Accustem Sciences’ Business AccuStem is a clinical-stage diagnostics company focusing solely on optimizing the quality of life and outcomes for cancer patients. Their flagship platform, StemPrintER, is truly exceptional. It's a 20-gene prognostic assay that predicts the risk of distant recurrence in cancer patients, and it's already got patents in the US and Europe. What makes StemPrintER stand out? It's been designed to measure the "stemness" of tumors. In simpler terms, it looks at how much a tumor behaves like a stem cell, which can indicate how likely the cancer is to come back or resist standard treatments. This critical information guides the patient's care team in tailoring their treatment approach, ensuring they get the best possible care. The hope is to improve outcomes while reducing healthcare costs. Their first target is early-stage breast cancer, a massive $1.3B global market. AccuStem is uniquely positioned here, offering something none of its competitors do. You see, unlike other assays used post-surgery to guide follow-up therapies, AccuStem's test is the only one designed for use at an earlier stage, right after biopsy, to inform the best surgical approach for patients. [6jlbambAjJcfczODgiwQ6Bbm_28CNJZ3q4k6jiG0XN6n_dKKV96nA_AG20xz3W67cWecBAbS2rnBbsAR6i6oQzvgfCESKdXRT2FbW1d5ggc0Fq5Cslc88IvAYU2P3pTRnY_QoEKonAuFSa7sxtW9Hc4] [Source: Accustem Investor Deck]( Despite its importance, no company has yet been able to design a test that hones in on cancer stem cell features and provides pre-surgery prognostic insights. That's until AccuStem arrived on the scene, having validated their approach in several clinical cohorts and studies. AccuStem plans to publish updated data in a peer-reviewed paper, establish a lab before launching their offering, and commence full commercialization, with reimbursement coverage by 2025. Early-stage lung cancer and localized prostate cancer are also on their radar. [pdlYzCVCr1hzgYTsmkY1Wp1FZ-5A56f8yFzBqJrKdcJAWsXDmDoJUjmUFjTrxD-CdLfkwSSW7ZsjOqUsT7z-eHKTHDcvYicX-Ddro820bbMUC6pCiErVKbyhfOUVjbHCubg17K3kBCuYLBa28BgnVqQ] [Source: Accustem Investor Deck]( So what about that uplisting? To fund all their efforts, the company plans to raise up to $11M in a secondary offering in the second half of 2023 and are eyeing a NASDAQ up-list, which would necessitate a reverse split of the shares. Financials [( With no products currently approved, Accustem doesn’t really generate revenues. However, [a report by Goldman Small Cap Research]( (not affiliated with Goldman Sachs), suggests the company could see sales around $5.8 million in 2025. [rySQi9aoQhzFNqsHidWRwyYu6dLWeYbmU5JBIhB3CqandqgLi430eMyWPBInf2lHigZdo84q3lSd1ueAMEAsOZWqCAiE_noxgTh9k6nBaQw4g8XuJ4sq3xUQBBwx7J56dCeMmi0jl3fUMv8eltT1IRQ] [Source: Goldman Small Caps Research]( HOWEVER, I want to point out Goldman was compensated $4,000 for its ‘research.’ Although I found it through non-traditional channels, I’d still classify this as a promoter. Nonetheless, it's more in-depth than most offer. Right now, the company burns about $500,000 a quarter with a few hundred thousand on its balance sheet. So, the uplisting and tender offer couldn’t come at a better time. Accustem plans to offer 1.48 million shares (1,478,495 shares) at $7.44, which accounts for the 6 for 1 reverse split. Promoter Activity I only received one promotion regarding ACUT. Interestingly, it didn’t list the compensation amount. In fact, it was rather short, only talking about one recent news event: June 06, 2023 - AccuStem Sciences announced establishing a joint clinical collaboration agreement with University Hospitals. Per the terms of this agreement, University Hospitals will provide tissue samples with clinical outcomes to AccuStem for research purposes. That’s really all they discussed. I found that rather odd considering the uplisting story plus their current Phase III trials. Both of these warrant mention, yet weren’t missing from the email. Straight to the Facts This company may never have a drug that makes it to market. But so long as that news doesn’t drop before it uplists, there is likely to be a TON of price action. We don’t know the exact date, just that it’s likely in the second half. I plan to keep tabs with Google and social media news alerts until this happens. You should consider the same. Baron Von Stocks Red Oak Media Group, 7940 Ann Arbor St Dexter MI USA 48130 To update contact information or unsubscribe from this list, please [click here](